LANCY(002612)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 reached ¥1,139,399,566.72, representing a 21.31% increase compared to ¥939,226,348.80 in the same period last year[13] - Net profit attributable to shareholders was ¥62,049,136.05, a significant increase of 6985.13% from a loss of ¥901,205.40 in the previous year[13] - The net cash flow from operating activities was ¥221,827,689.62, up 166.78% from ¥83,149,801.78 in the same period last year[13] - Basic and diluted earnings per share were both ¥0.1402, a substantial increase of 2849.02% from -¥0.0051 in the previous year[13] - The company achieved a 30.68% increase in revenue from its medical beauty business, totaling ¥45,904.01 million[13] - Operating profit for the current period was ¥67,084,783.35, a substantial increase of 667.03% from a loss of ¥11,830,946.94 in the previous year[32] - Total revenue for the first quarter reached ¥1,139,399,566.72, an increase of 21.3% compared to ¥939,226,348.80 in the same period last year[44] - The company's net profit attributable to shareholders was not explicitly stated, but the retained earnings increased to ¥819,529,704.42 from ¥757,480,568.37, indicating a growth of 8.2%[43] - The net profit for the period was $57.26 million, compared to a net loss of $8.39 million in the same period last year[49] - Earnings per share (EPS) for the current period was $0.1402, a recovery from a loss of $0.0051 per share in the previous year[49] Cash Flow and Investments - The net cash flow from financing activities was -$63.77 million, compared to -$223.94 million in the previous period, indicating an improvement[48] - The net increase in cash and cash equivalents was $51.67 million, contrasting with a decrease of $90.89 million in the prior period[48] - Operating cash flow generated was $221.83 million, a significant increase from $83.15 million year-over-year[51] - The total cash inflow from operating activities was $1.18 billion, compared to $1.06 billion in the previous year, showing a growth of about 10.8%[51] - Cash outflows from investing activities totaled $120.51 million, a decrease from $358.62 million in the prior year, indicating reduced investment expenditures[51] - The company reported a net investment income of ¥30,845,384.18, significantly higher than ¥10,955,085.73 from the previous year, marking an increase of 181.5%[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,052,712,529.26, reflecting a slight decrease of 0.81% from ¥7,110,249,238.41 at the end of the previous year[23] - The total liabilities increased to ¥3,417,115,780.85 from ¥3,492,390,072.87, a decrease of 2.1%[43] - Long-term borrowings increased to ¥70,000,000.00, marking a 100% increase due to new long-term loans taken during the period[17] - The company's trading financial assets increased by 273.94% to ¥20,652,672.95, up from ¥5,523,031.04 at the end of the previous year[17] - The total assets of the company were ¥7,052,712,529.26, down from ¥7,110,249,238.41, indicating a decrease of 0.8%[43] Shareholder Information - The company reported a total of 69,396 common shareholders at the end of the reporting period, with the largest shareholder holding 47.82% of the shares[24] - Shareholders' equity attributable to the parent company was ¥2,927,047,166.38, a 1.69% decrease from ¥2,878,340,308.08 at the end of the previous year[23] Expenses and Costs - Total operating costs amounted to ¥1,078,495,518.34, up from ¥933,074,035.42, reflecting a rise of 15.6% year-over-year[44] - Research and development expenses for the quarter were ¥23,045,991.84, down from ¥29,054,299.01, a decrease of 20.7%[44] - The company reported a 31.00% increase in payable employee compensation, totaling ¥43,348,585.08, due to increased performance incentives related to the growth in medical beauty business revenue[17]